Physician profile
Manmeet Kaur
NPI 1053555334
$43,666.43
in general payments reported to CMS, 2019-2025
29 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $323 · 2022: $652 · 2023: $900 · 2024: $753 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $74.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.74 |
| Education | $74.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38,375.29 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $1,236.69 | 2019-2025 | Ozempic, Sogroya, Norditropin |
| Valeritas, INC. | $758.22 | 2019 | |
| Dexcom, INC. | $542.59 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $518.01 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $375.35 | 2022-2025 | Evenity, Prolia, Tepezza |
| Amryt Pharma Holdings Ltd | $221.69 | 2023 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $189.63 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $180.43 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $174.57 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $133.61 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals Lp | $117.59 | 2022 | |
| Radius Health, INC. | $106.40 | 2021 | |
| Insulet Corporation | $106.11 | 2023-2025 | Omnipod |
| Abbvie INC. | $98.67 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $86.64 | 2025 | |
| Cequr Corporation | $73.60 | 2022-2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $60.64 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $57.58 | 2023-2024 | Strensiq |
| Medtronic, INC. | $42.76 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $35.57 | 2025 | |
| Embecta Corp. | $28.64 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $26.31 | 2024 | |
| Sequel Med Tech, LLC | $24.48 | 2025 | Twiist |
| Halozyme INC | $24.38 | 2023 | |
| Almatica Pharma LLC | $21.77 | 2025 | Teriparatide |
| Sanofi-Aventis U.S. LLC | $18.93 | 2022 | |
| Recordati_rare_diseases_inc. | $15.84 | 2023 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $14.44 | 2025 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmeet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.